Is Glaxo's niche-drug strategy a sleeper?

GlaxoSmithKline CEO Andrew Witty (photo) answers a U.K. broadcaster's question: If Glaxo isn't going to develop blockbuster meds, then who is? It doesn't impress PharmaGossip, which proposes the broadcast as a preternaturally effective insomnia treatment. (Video) Report | Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.